Articles tagged with Cervical Cancer
The USPSTF has updated its recommendations for cervical cancer screening, varying by age and risk factors. Most cases occur among women who haven't been adequately screened, leading to a decrease in deaths from cervical cancer since widespread screening began.
The US Preventive Services Task Force recommends screening for cervical cancer every three to five years with primary hrHPV test alone or co-testing. This new approach aims to reduce participant burden and increase efficiency in cervical cancer screening.
A comprehensive analysis found high-risk HPV testing excellent for detecting pre-cancerous cells and cancer, with a higher detection rate compared to Pap smears. The research also showed that while high-risk HPV tests are effective, they can lead to more treatments with potential harms due to false positives.
The study, conducted by the University of Sheffield, found that 2.2% of participants were infected with high-risk human papillomavirus (HR-HPV) oral infection, lower than previous US studies. Smoking and sexual behavior were identified as significant risk factors for oral HPV infection.
A new study published in Obstetrics & Gynecology found that the Patient Protection and Affordable Care Act (ACA) has led to an earlier diagnosis of gynecologic cancers in young women, resulting in improved health outcomes and increased survival rates. The study analyzed data from the National Cancer Database and found a significant dec...
Primary HPV testing detects precancerous lesions earlier and more accurately than Pap smears, according to a large randomized clinical trial of nearly 19,000 women. Women who were HPV negative were also less likely to have cervical pre-cancer after four years.
A study by the University of Arizona Cancer Center found that women with cervical cancer have different communities of vaginal bacteria than those without. The 'good' bacteria, such as lactobacilli, promote a healthy environment and protect against HPV infection and cancer, while 'bad' bacteria like Sneathia increase cancer risk. Hispa...
A great majority of Mozambican adolescent girls (around 80%) are aware that cervical cancer can be prevented and over 90% willing to receive the vaccine. The introduction of HPV vaccination is urgent in sub-Saharan Africa, where cervical cancer is a major cause of mortality among women.
The study reveals a universal increase in lifestyle-related cancers between 2006 and 2016, with significant disparities persisting between high- and low-Socio-demographic Index countries. Breast cancer is the leading cause of cancer death in women, while lung cancer tops the list for men, accounting for nearly 20% of global cancer deaths.
New research from two large international trials confirms that intracavitary and interstitial brachytherapy is safe and does not increase the risk of ureteral stricture in cervical cancer patients. The treatment is associated with better survival rates and fewer adverse side effects compared to other radiation therapies.
A new study suggests that high-quality cervical cancer screening can be effectively done using automated technology, which could improve coverage in underserved regions. The researchers developed a novel risk score algorithm based on computer-scanned liquid-based slide features to separate HPV-positive women for treatment.
A large study found that Métis adults have higher rates of lung, liver, and breast cancers, as well as poorer prostate cancer survival rates. The study also identified lower incidence rates for melanoma and leukemia in Métis adults compared to non-Aboriginal people.
Researchers from the University of Pennsylvania School of Nursing used implementation science to evaluate cervical cancer prevention programs in sub-Saharan Africa. They identified a need for additional organizational and structural support to sustain implementation and improve cervical cancer prevention.
Two University of Houston researchers are investigating estrogen's potential as a cause of cervical cancer. Using CPRIT funding, Sanghyuk Chung is examining the role of estrogen receptor alpha in stromal cells surrounding cancer cells, which may lead to a targeted therapy for cervical cancer treatment.
A new study published in the British Journal of Cancer found that self-sampling followed by HPV testing can identify twice as many women at risk of cervical cancer. This method also reaches women who have previously chosen not to participate, while reducing costs and increasing effectiveness.
Researchers at WashU Medicine developed a new approach to combat cervical cancer by targeting the tumor's fuel supply. A combination of radiation and three drugs that cut off glucose metabolism effectively shuts down tumor metabolism, making it vulnerable to treatment.
Researchers found that standard practices for comparing cervical cancer radiation therapy treatments may be misleading. A new mathematical formula could improve outcomes by providing more accurate predictions and personalization of treatment plans.
A new study from the University of Gothenburg suggests that higher education and income are key factors determining whether women participate in cervical screening. The study, which analyzed data from over 581,000 women, found that country of birth was not a significant factor in participation rates.
Researchers found combining blueberry extract with radiation increases treatment effectiveness for late-stage cervical cancer, reducing healthy cell damage by up to 70%. The study's lead author suggests blueberries as a potential radiosensitizer, a non-toxic chemical that enhances cancer cells' responsiveness to radiation therapy.
Research led by Queen Mary University of London predicts a shift in cervical cancer burden from young to older women. Incidence among 50-54 year olds is expected to increase by 50%, while mortality rates are projected to rise by 109% among 60-64 year olds.
Researchers at NUS Cancer Science Institute discovered a molecular pathway in which TIP60 inhibits cancer cell growth by targeting telomerase. This finding offers a new approach to treating various types of cancer triggered by high telomerase levels.
A decade-long study on hundreds of HPV vaccine recipients found the vaccine to be safe and effective in preventing the most virulent strains of the virus. The quadrivalent vaccine was virtually 100% effective in preventing disease in young individuals.
A study found that only 20% of Indonesian women are aware of cervical smears, with even lower rates for mammography. Higher education, household expenditure, and health insurance were associated with increased awareness and participation. Experts call for improved education and access to resources to increase cancer screening rates.
A new study finds that HPV testing is more sensitive than the Pap test for detecting precancerous cells. Cotesting, which combines both methods, identified more cases of treatable cancer but only affected a small number of women.
A new study suggests that HPV vaccination can reduce the number of cervical screens needed from 12 to just three for vaccinated women. The research also recommends seven lifetime screens for unvaccinated women.
A comprehensive study from the Keck School of Medicine of USC found that IUD use is associated with a dramatic decrease in cervical cancer incidence. The analysis included data from 16 high-quality observational studies involving over 12,000 women worldwide.
A new study found significant disparities in survival rates for patients with different types of human papillomavirus (HPV)-associated cancers. The findings highlight the need for improved HPV vaccination, cancer screening, and treatment access to address these disparities.
A study has identified a new strategy to treat HPV-related cancers, targeting the virus's E6 oncoprotein and its interaction with myc protein. This approach could lead to a more specific and less toxic treatment option.
The study found that four fractions of 7 Gy HDR brachytherapy resulted in significantly better tumor control than two 9-Gy fractions, with a higher survival rate for women with stage IIB disease. Severe treatment-related side effects did not differ significantly between treatment arms.
Female cancer survivors face increased risks of preterm birth and small for gestational age infants after diagnosis. Certain cancers, such as cervical, breast, leukemia, brain cancer, and extranodal non-Hodgkin lymphoma, are linked to poorer pregnancy outcomes.
A randomized trial of over 600 patients confirms chemoradiation as the standard treatment for locally advanced cervical cancer, with no improved disease-free survival seen with neoadjuvant chemotherapy followed by surgery. The findings suggest that chemoradiation should remain the standard treatment.
A new study published in LGBT Health suggests that alternative cervical cancer screening methods, such as HPV self-sampling, can increase screening rates among transgender men. The research found that over half of participants preferred HPV self-sampling and had not received a Pap smear within the previous three years.
Researchers have found that human papillomavirus 16 (HPV16) infections can have varying levels of cancer risk due to unique genetic variations. Studies revealed thousands of distinct HPV16 genomes in infected individuals, with some variants linked to increased carcinogenic potential.
The new 9vHPV vaccine targets nine high-risk HPV types, significantly reducing the risk of cervical cancer, genital warts, and HPV-related vulvar and vaginal cancers. The study found that the vaccine is highly effective in preventing HPV infection and disease, with a 97.7% reduction in risk.
A new study published in The Lancet found that the Gardasil 9 vaccine can reduce 90% of cervical cancer cases with long-term effectiveness. The vaccine was tested on over 14,000 women worldwide and showed similar safety profiles to the four-valent HPV vaccine.
A change in cervical cancer screening guidelines led to a decrease in Pap testing and chlamydia testing among young women. Chlamydia testing declined by 26% in females aged 15-19, resulting in lower reported incidence rates for this age group.
Research confirms a positive correlation between HPV vaccination and increased cervical screening rates, contradicting concerns about reduced screening due to reassurance. However, vaccine cost and provider recommendations remain significant barriers to widespread adoption in the US.
A new study found that home-based HPV self-sampling is an acceptable way to participate in cervical cancer screening programs. Most women chose self-sampling due to its convenience, privacy, and reduced embarrassment.
A study of Senegalese women found that HIV-positive women were more likely to acquire human papillomavirus (HPV) infection and have it progress to precancerous lesions. The research highlights the importance of targeted cervical cancer prevention efforts for high-risk HIV-positive populations.
Researchers at Duke University have developed a handheld device for cervical cancer screening that can capture images of the cervix without a speculum or trained professional. The 'pocket colposcope' is designed to be low-cost, accessible, and potentially self-screening.
Around half of women with locally advanced cervical cancer experience symptoms like fatigue, insomnia, and hot flushes after treatment. Younger women are more likely to be affected. Research highlights the need for better recognition and treatment of these under-recognised symptoms.
A new study found that cervical cancer incidence rates among women without a hysterectomy increase with age until 70 and do not begin to decline until 85. Many women over 65 have inadequate screening history, highlighting the need for continued surveillance.
A therapeutic vaccine is being tested to prevent or reduce cervical cancer recurrence in women at high risk. The vaccine has shown promise in extending survival time for patients with recurrent disease, and its safety and efficacy are being evaluated in a phase 3 study.
A new AI-based image detection method has shown promise in screening for cervical cancer, detecting abnormalities with higher sensitivity and specificity than traditional methods. The technique, developed by Lehigh University researchers, could be used to improve early detection and treatment of the disease in resource-poor regions.
A study of California Medicaid recipients with severe mental illness found low cervical cancer screening rates, with only 20.2% screened compared to 42.3% in the general population. Younger women and those from minority groups had higher screening rates, but there was still a significant disparity in cervical cancer development risk.
Researchers found a genetic variant associated with reduced HPV infection and cervical cancer risk in Saudi Arabia. This variant may be more common in populations with lower cervical cancer incidence rates.
The American Society of Clinical Oncology has released a clinical practice guideline on human papillomavirus (HPV) vaccination for the prevention of cervical cancer. The guideline offers evidence-based recommendations for four levels of resource settings, providing guidance to health care providers worldwide.
Dr. Navkiran Shokar is expanding the De Casa En Casa program to provide free cervical cancer screenings and education to rural counties in Texas, aiming to increase screening rates from 63-71% to 82% nationally. The grant will also train local nurses and community health workers to promote awareness of cervical cancer and its symptoms.
A study found that fewer than three out of five women with locally advanced cervical cancer received guideline-based care, with black and Hispanic women receiving lower rates. Despite an increase in guideline-based care over time, disparities persist, highlighting the need for further investigation into barriers to treatment.
Researchers found that cytology was very sensitive and consistent for detecting invasive cervical cancer even in low-resource settings. Cytology may be used to diagnose cervical cancer earlier in women at high risk, leading to improved overall survival from the disease.
A new, multidisciplinary model of cervical cancer care developed by a University of Pennsylvania team in Botswana cut the delay between diagnosis and treatment by more than 50 percent. The model streamlined care and communication between providers, reducing delays in treatment and simplifying the overall process.
Researchers at OIST have developed a novel technique that targets lipid rafts on cancer cell membranes to block migration. The molecule works by physically pinning the cancer cell, causing it to rupture and leading to cell death.
A new special issue of Preventive Medicine analyzes the shift from cytology to HPV testing for cervical cancer screening, citing improved efficiency and accuracy. Experts endorse HPV testing as a better option, but acknowledge the challenges of implementing changes globally.
Analysis of US data from 2002 to 2012 reveals significantly higher cervical cancer mortality rates among black women (77% higher) and white women (47% higher), with disparities increasing over time. Black women's corrected mortality rate is 10.1 per 100,000 women, compared to 5.7 for uncorrected rates.
New research suggests cervical cancer death rates are higher among older and black women in the US, particularly due to exclusion of women who have had hysterectomies. This discrepancy highlights the need for better screening and treatment options for these groups.
Researchers identified novel genomic characteristics of cervical cancer, including cell signaling pathways and human papillomavirus (HPV) infection. The study also found amplification of genes involved in immune responses and potential therapeutic targets.
Researchers identified a new subtype of cervical cancer with distinct genomic pathways, potentially benefiting from alternative treatments. The study found significant differences in tumor characteristics between HPV-active and -inactive subtypes.
A new study reveals that women with advanced kidney disease are at a higher risk of developing cancer, highlighting the importance of targeted screening strategies.
Researchers developed a novel urine test to predict high-risk cervical cancer with 90.9% accuracy using genetic markers from HPV and human cells. The test shows promise as a cost-effective alternative to existing methods, which may be unnecessary in up to 50% of cases.
A report from Merck KGaA and the American Cancer Society highlights that four top cancer causes in women are mostly preventable or can be detected early, leading to more successful treatment. The number of women who will lose their lives to cancer is expected to increase by 57% from 3.5 million in 2012 to 5.5 million by 2030.